Appili Therapeutics Inc. (APLI.H)
TSXV
Closed
Oct 30, 2026
Day's Range
0.0050052 wk Range
0.00500Overview - APLI.H - Appili Therapeutics Inc.
Key Statistics
Valuation
Enterprise Value
13.84M
Price / Sales (TTM)
1.82
EV / EBITDA
-2.12
Profitability
Profit Margin
0.00%
Operating Margin
-1,368.86%
Return on Assets
-255.65%
Ownership
Shares Outstanding
132.36M
Float
117.93M
Held by Insiders
0.05%
Held by Institutions
10.84%
Price stats
Beta
0.14
50-Day Avg
0.00980
200-Day Avg
0.0148
Market Cap - APLI.H - Appili Therapeutics Inc.
Peers - APLI.H - Appili Therapeutics Inc.
Peer Comparison
Compared with companies in Biotechnology listed on TSXV.
- APLI.HTSXVAppili Therapeutics Inc.661.83KMarket Cap-100.00%52-week change—P/E (Trailing)0.00%Profit Margin
- ARCHTSXVArch Biopartners Inc.58.42MMarket Cap-23.26%52-week change-35.83P/E (Trailing)0.00%Profit Margin
- AURATSXVAuranova Resources Inc.15.41MMarket Cap-195.00%52-week change-1.20P/E (Trailing)0.00%Profit Margin
- AZRTSXVAzarga Metals Corp.10.51MMarket Cap+4.35%52-week change—P/E (Trailing)0.00%Profit Margin
- ALTTSXVAlturas Minerals Corp.2.91MMarket Cap+50.00%52-week change—P/E (Trailing)0.00%Profit Margin
- BSTTSXVBessor Minerals Inc.625.71KMarket Cap-100.00%52-week change-2.00P/E (Trailing)0.00%Profit Margin
Profile Summary - APLI.H - Appili Therapeutics Inc.
About
Appili Therapeutics Inc. is a Canadian biopharmaceutical company focused on developing treatments for infectious diseases and medical countermeasures. Its current portfolio includes LIKMEZ, a liquid oral formulation of metronidazole designed for anaerobic bacterial and protozoal infections, as well as ATI-1801, a…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
